Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim drug ‘significantly reduces knee pain’

Boehringer Ingelheim drug ‘significantly reduces knee pain’

2nd February 2009

Boehringer Ingelheim’s Cymbalta drug reduces osteoarthritis-associated knee pain, according to a study.

A 13-week randomised, double-blind and placebo-controlled clinical trial found 65 per cent of patients experienced a lowering in the level of discomfort that arises from the condition, in comparison to 44 per cent of people who received placebo.

The study also noted subjects on the drug – which is administered at 60 or 120 mg doses once a day – had improved physical function.

Commenting on the findings, Jacques Brown of the Rheumatology and Bone Diseases Research Group in Quebec City, Canada, said the number of people suffering from osteoarthritis of the knee is expected to rise as a result of an aging population.

He added: “This condition can have a real impact on a person’s life, limiting functionality and ability to perform day-to-day activities.”

In December, a study found Duloxetine – also manufactured by Boehringer Ingelheim – delayed the onset of a new depression episode in patients who have recurrent depressive disorder.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.